4.63
-1.49%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Huapont Life Sciences Co
Its shares trade on Shenzhen under the ticker 002004.SZ. It has been listed since 25 June 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥11.51bn and net income of CN¥713.2m. At that date it held total assets of CN¥29.03bn and shareholders' equity of CN¥10.22bn.
Huapont Life Sciences Co., Ltd. engages in the manufacture of chemical raw materials. The company is headquartered in Chongqing, Chongqing. The company went IPO on 2004-06-25. The firm operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The firm is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 25 Jun 2004
- Employees
- 12,476
- Website
- huapont.com.cn ↗
Leadership
Pay as last reported
- Mr. Songshan ZhangChairman of the Board, since 1994CN¥1.8m
- Mr. Jian WangChief Financial OfficerCN¥482,600
- Mr. Hai'an ZhangGeneral Manager, Director, since 2018CN¥1.7m
- Ms. Yunhui PengSecretary of the Board, Director, since 2001CN¥847,000
- Mr. Rong WangDirectorCN¥1.9m
- Mr. Ming LiIndependent DirectorCN¥142,900
- Mr. Zhonghai LiuIndependent DirectorCN¥142,900
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 36
- Social
- 21
- Governance
- 67
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Huapont Life Sciences employs 12,476 full-time employees in Chongqing, China.
- The company manufactures fleroxacin and ambroxol hydrochloride for injection in its Pharmaceutical segment.
- Huapont Life Sciences produces lecithin-bound iodine capsules and other skin pharmaceuticals.
Weaknesses
- The company's Pesticide Chemical segment focuses on herbicides, bactericides, and insecticides.
- Huapont Life Sciences operates in the Materials sector with Chemicals industry.
- The firm's Bulk Drug segment develops medical intermediates and bulk drugs.
Opportunities
- Huapont Life Sciences could expand its Pharmaceutical segment with new skin pharmaceuticals.
- The Pesticide Chemical segment may grow with increased demand for herbicides.
- Huapont Life Sciences might develop new medical intermediates in its Bulk Drug segment.
Threats
- Huapont Life Sciences faces competition from other Chemicals manufacturers in China.
- The company's reliance on Chongqing for operations poses location-specific risks.
- Huapont Life Sciences must navigate regulatory changes in the Pharmaceuticals industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.